Biotechnology - Licensing, Antibiotics and Infectious diseases

Filter

Popular Filters

Valneva initiates fourth antibody discovery program for Sanofi Pasteur

25-02-2014

European biotechnology company Valneva has initiated a fourth monoclonal antibody discovery program for…

Antibiotics and Infectious diseasesBiotechnologyLicensingResearchSanofiSanofi PasteurVaccinesValneva

Soligenix and Intrexon collaborate on Melioidosis therapy development

01-05-2013

US clinical stage biopharma company Soligenix (OTCBB: SNGX) says it will jointly develop a treatment…

Antibiotics and Infectious diseasesBiotechnologyIntrexonLicensingPharmaceuticalResearchSoligenix

Termination of Shigamabs deal with LFB Biotech leads Thallion to review options

21-02-2013

Canada-based Thallion Pharmaceuticals (TSX VENTURE: TLN) and LFB Biotechnologies of France have terminated…

Antibiotics and Infectious diseasesBiotechnologyLFB BiotechnologiesLicensingShigamabsThallion Pharmaceuticals

NeRRe Therapeutics created to develop NRAs from GSK; GlycoVaxyn deal with GSK

20-12-2012

NeRRe Therapeutics was launched in the UK yesterday to develop a portfolio of clinical and pre-clinical…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineGlycoVaxynLicensingNeRReTherapeuticsNeurologicalNovo NordiskPharmaceuticalResearchVaccines

GlaxoSmithKline amends accord with Isis Pharma; gets FDA panel backing for raxibacumab

06-11-2012

USA-based Isis Pharmaceuticals (Nasdaq: ISIS) says it has agreed to amend the clinical development plan…

Antibiotics and Infectious diseasesBiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR.RXLicensingNorth AmericaPharmaceuticalRare diseasesraxibacumabRegulationResearch

NovaBay entering transformational period, say Edison analysts

10-09-2012

US biotech firm NovaBay Pharmaceutical (Nasdaq: NBY) is entering a potentially transformational 12-month…

Antibiotics and Infectious diseasesBiotechnologyFinancialLicensingNeutroPhaseNovaBay PharmaceuticalNVC422Research

News briefs: TB drug developments at Jansen and AstraZeneca; NPS/Amgen deal amended

03-07-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Research & Development unit has submitted…

AmgenAntibiotics and Infectious diseasesAstraZenecabedaquilineBiotechnologyCellworkscinacalcetJanssenJohnson & JohnsonLicensingMetabolicsNPS PharmaceuticalsPharmaceuticalRegulationResearch

TaiGen Biotech out-licenses China rights for nemonoxacin, to Zhejiang Medicine

26-06-2012

Taiwan-based TaiGen Biotechnology and China's Zhejiang Medicine Company (SHA: 600216) have signed an…

Antibiotics and Infectious diseasesAsia-PacificBiotechnologyLicensingnemonoxacinPharmaceuticalTaiGen BiotecnologyZhejiang Medicine

Forest acquires rights to Nabriva antibacterial and option to buy firm

04-06-2012

US drugmaker Forest Laboratories (NYSE: FRX) says it has entered into an agreement with Austrian biotech…

Antibiotics and Infectious diseasesBC-3781BiotechnologyForest LaboratoriesLicensingMergers & AcquisitionsNabriva TherapeuticsPharmaceutical

TaiGen gets global nemonoxacin rights

11-12-2011

Taiwan’s TaiGen Biotechnology has reached a deal with Ireland-headquartered Warner Chilcott (Nasdaq:…

Antibiotics and Infectious diseasesBiotechnologyLicensingnemonoxacinPharmaceuticalTaiGen BiotecnologyWarner Chilcott

Sanofi Pasteur and CureVac collaborate on a $33.1 million project on vaccines for infectious diseases

16-11-2011

Germany’s CureVac says it has signed several agreements with Sanofi Pasteur, the vaccines division…

Antibiotics and Infectious diseasesBiotechnologyCureVacLicensingPharmaceuticalResearchSanofiSanofi PasteurVaccines

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top